Security
Phathom Pharmaceuticals, Inc. Common Stock · PHAT
PHATNASDAQCommon stockCurrentCIK 1783183Updated Nov 3, 2026
PHAT price & chart
Loading TradingView…
NASDAQ:PHAT on TradingView ↗About the company
Phathom Pharmaceuticals is a biopharmaceutical company focused on the commercialization and development of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.
In the news
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Other Events
Items 8.01
Other Events
Items 8.01
Other Events
Items 8.01
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Other Events
Items 8.01
4 filing
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 240,289,000Source | 387,044,000Source | 327,075,000Source | 250,220,000Source | 319,376,000Source | 305,120,000Source | 294,208,000Source | 356,499,000Source | 259,149,000Source | 378,318,000Source | 413,842,000Source | 164,810,000Source |
| Property, Plant and Equipment, NetUSD | 1,156,000Source | 1,655,000Source | 971,000Source | 1,242,000Source | 1,813,000Source | 1,016,000Source | 1,354,000Source | 1,962,000Source | 1,064,000Source | 1,476,000Source | 2,146,000Source | 1,207,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 135,156,000Source | 334,678,000Source | 182,478,000Source | 149,569,000Source | 276,237,000Source | 180,904,000Source | 212,315,000Source | 322,229,000Source | 129,972,000Source | 297,263,000Source | 381,393,000Source | 155,385,000Source |
| Inventory, NetUSD | 3,611,000Source | 3,111,000Source | 7,713,000Source | 3,431,000Source | 2,177,000Source | 6,508,000Source | 3,166,000Source | 1,458,000Source | 5,518,000Source | 3,208,000Source | 1,208,000Source | — |
| Assets, CurrentUSD | 207,783,000Source | 373,821,000Source | 295,915,000Source | 218,875,000Source | 304,788,000Source | 276,571,000Source | 264,900,000Source | 340,314,000Source | 228,972,000Source | 360,134,000Source | 397,432,000Source | 160,512,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 13,227,000Source | 14,980,000Source | 8,302,000Source | 14,620,000Source | 15,497,000Source | 8,435,000Source | 13,055,000Source | 12,748,000Source | 15,353,000Source | 20,866,000Source | 13,194,000Source | 5,127,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,694,000Source | 833,000Source | 2,410,000Source | 873,000Source | 1,050,000Source | 2,508,000Source | 388,000Source | 1,264,000Source | 2,603,000Source | 613,000Source | 1,475,000Source | 2,287,000Source |
| Other Assets, NoncurrentUSD | 1,693,000Source | 1,692,000Source | 3,088,000Source | 1,693,000Source | 1,692,000Source | 3,088,000Source | 1,693,000Source | 1,692,000Source | 2,917,000Source | 1,693,000Source | 1,692,000Source | 299,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 662,823,000Source | 574,156,000Source | 671,348,000Source | 656,054,000Source | 553,205,000Source | 642,075,000Source | 632,584,000Source | 505,002,000Source | 697,318,000Source | 631,898,000Source | 486,601,000Source | 239,624,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 6,000Source | 6,000Source | 8,000Source | 6,000Source | 5,000Source | 7,000Source | 6,000Source | 5,000Source | 6,000Source | 6,000Source | 5,000Source | 3,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,463,110,000Source | -1,188,560,000Source | -1,532,209,000Source | -1,433,137,000Source | -1,102,983,000Source | -1,514,627,000Source | -1,357,327,000Source | -1,011,537,000Source | -1,484,258,000Source | -1,263,011,000Source | -928,685,000Source | -727,093,000Source |
| Stockholders' Equity Attributable to ParentUSD | -422,534,000Source | -187,112,000Source | -344,273,000Source | -405,834,000Source | -233,829,000Source | -336,955,000Source | -338,376,000Source | -148,503,000Source | -438,169,000Source | -253,580,000Source | -72,759,000Source | -74,814,000Source |
| Additional Paid in Capital, Common StockUSD | 1,040,570,000Source | 1,001,442,000Source | 1,187,928,000Source | 1,027,297,000Source | 869,149,000Source | 1,177,665,000Source | 1,018,945,000Source | 863,029,000Source | 1,046,083,000Source | 1,009,425,000Source | 855,921,000Source | 652,276,000Source |
| Liabilities and EquityUSD | 240,289,000Source | 387,044,000Source | 327,075,000Source | 250,220,000Source | 319,376,000Source | 305,120,000Source | 294,208,000Source | 356,499,000Source | 259,149,000Source | 378,318,000Source | 413,842,000Source | 164,810,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 93,123,000Source | 65,288,000Source | 153,777,000Source | 91,823,000Source | 47,009,000Source | 125,041,000Source | 74,032,000Source | 43,459,000Source | 132,044,000Source | 85,728,000Source | 38,781,000Source | 26,237,000Source |
| Operating Lease, Liability, CurrentUSD | 591,000Source | 680,000Source | 670,000Source | 238,000Source | 720,000Source | 667,000Source | 316,000Source | 730,000Source | 648,000Source | 501,000Source | 726,000Source | 708,000Source |
| Accounts Payable, CurrentUSD | 1,075,000Source | 7,133,000Source | 5,361,000Source | 4,008,000Source | 7,656,000Source | 6,365,000Source | 11,617,000Source | 8,403,000Source | 4,983,000Source | 10,507,000Source | 12,601,000Source | 9,997,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,123,000Source | 0Source | 1,855,000Source | 589,000Source | 133,000Source | 1,961,000Source | 0Source | 292,000Source | 2,065,000Source | 0Source | 462,000Source | 1,098,000Source |
| Other Liabilities, NoncurrentUSD | 11,500,000Source | 10,750,000Source | 3,500,000Source | 11,500,000Source | 10,450,000Source | 3,500,000Source | 11,500,000Source | 9,700,000Source | 4,000,000Source | 11,500,000Source | 9,700,000Source | 7,500,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 65,349,000Source | 35,759,000Source | 109,027,000Source | 64,296,000Source | 27,298,000Source | 83,317,000Source | 43,028,000Source | 16,541,000Source | 89,831,000Source | 53,232,000Source | 17,197,000Source | 14,678,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 207,093,000Source | 175,729,000Source | 164,587,000Source | 205,139,000Source | 174,423,000Source | 163,675,000Source | 203,245,000Source | 149,023,000Source | 209,087,000Source | 201,409,000Source | 137,842,000Source | 95,264,000Source |
| Long-term Debt, Current MaturitiesUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 207,093,000Source | 175,729,000Source | 164,587,000Source | 205,139,000Source | 174,423,000Source | 163,675,000Source | 203,245,000Source | 149,023,000Source | 209,087,000Source | 201,409,000Source | 137,842,000Source | 95,264,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -30,369,000Source | -94,316,000Source | -221,247,000Source | -334,326,000Source | -201,592,000Source | -197,723,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 110,000Source | 177,000Source | 633,000Source | 795,000Source | 575,000Source | 620,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 5,534,000Source | 5,540,000Source | 28,719,000Source | 24,047,000Source | 45,025,000Source | 24,133,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 2,596,000Source | -2,433,000Source | 39,331,000Source | 37,160,000Source | 1,637,000Source | — |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -665,000Source | 12,328,000Source | 11,781,000Source | 6,142,000Source | 9,442,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -15,647,000Source | -84,930,000Source | -166,775,000Source | -266,770,000Source | -137,580,000Source | -146,530,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -61,000Source | -18,000Source | -229,000Source | -135,000Source | -1,634,000Source | -1,041,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 61,000Source | 18,000Source | 229,000Source | 135,000Source | 1,634,000Source | 1,041,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 66,640,000Source | 0Source | -288,000Source | 182,774,000Source | 367,580,000Source | 120,042,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 50,932,000Source | -84,948,000Source | -167,292,000Source | -84,131,000Source | 228,366,000Source | -27,529,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 4,936,000Source | 5,226,000Source | 21,368,000Source | 17,293,000Source | 11,133,000Source | 7,033,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 9,297,000Source | 5,635,000Source | 6,712,000Source | 8,272,000Source | 5,534,000Source | 5,540,000Source | 28,719,000Source | 24,047,000Source | 45,025,000Source | 24,133,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | 844,000Source | 696,000Source | 3,014,000Source | 2,192,000Source | 1,877,000Source | 2,110,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | — | — | — | 600,000Source |
| General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 100,999,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 16,108,000Source | 18,484,000Source | 15,103,000Source | 17,518,000Source | 15,797,000Source | 18,071,000Source | 68,115,000Source | 72,009,000Source | — | — |
| Inventory Write-downUSD | — | — | — | — | — | — | 0Source | 899,000Source | 280,000Source | 836,000Source | — | — |
| Investment Income, InterestUSD | — | — | 1,413,000Source | 3,711,000Source | 1,510,000Source | 1,787,000Source | 1,736,000Source | 2,640,000Source | 7,044,000Source | 15,158,000Source | 7,876,000Source | 2,132,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -29,973,000Source | -85,577,000Source | -17,582,000Source | -75,810,000Source | -30,369,000Source | -94,316,000Source | -221,247,000Source | -334,326,000Source | -201,592,000Source | -197,723,000Source |
| Nonoperating Income (Expense)USD | — | — | -14,702,000Source | -14,781,000Source | -13,617,000Source | -15,886,000Source | -14,892,000Source | -15,453,000Source | -61,261,000Source | -56,859,000Source | -34,280,000Source | -25,283,000Source |
| Operating ExpensesUSD | — | — | 58,585,000Source | 84,792,000Source | 63,143,000Source | 94,389,000Source | 61,782,000Source | 103,658,000Source | 312,497,000Source | 324,746,000Source | 167,827,000Source | 172,440,000Source |
| Operating Lease, ExpenseUSD | — | — | 200,000Source | 300,000Source | 200,000Source | 300,000Source | 200,000Source | 300,000Source | 1,000,000Source | 1,100,000Source | 1,100,000Source | 1,000,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -7,000Source | -8,000Source | -24,000Source | -155,000Source | -831,000Source | -22,000Source | -190,000Source | -8,000Source | -188,000Source | -110,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | 173,250,000Source | 0Source | 0Source | 59,400,000Source | 39,318,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 591,000Source | 0Source | 1,638,000Source | 1,599,000Source | 124,000Source | — |
| Repayments of Long-term Debt | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Gain (Loss) on Extinguishment of Debt | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 49,504,000Source | 16,352,000Source | 74,274,000Source | 39,503,000Source | 58,301,000Source | 28,519,000Source | 175,110,000Source | 55,252,000Source | 682,000Source | — |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | — |
| Selling, General and Administrative ExpenseUSD | — | — | 51,558,000Source | 76,099,000Source | 55,330,000Source | 85,313,000Source | 54,011,000Source | 94,474,000Source | 279,717,000Source | 290,664,000Source | 117,928,000Source | — |
| Operating Income (Loss)USD | — | — | -15,271,000Source | -70,796,000Source | -3,965,000Source | -59,924,000Source | -15,477,000Source | -78,863,000Source | -159,986,000Source | -277,467,000Source | -167,312,000Source | -172,440,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -7,000Source | -8,000Source | -24,000Source | -155,000Source | -831,000Source | -22,000Source | -190,000Source | -8,000Source | -188,000Source | -110,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -221,247,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -29,973,000Source | -85,577,000Source | -17,582,000Source | -75,810,000Source | -30,369,000Source | -94,316,000Source | -221,247,000Source | -334,326,000Source | -201,592,000Source | -197,723,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.41Source | -1.32Source | -0.21Source | -1.05Source | -0.37Source | -1.31Source | -3.03Source | -5.29Source | -3.93Source | -5.05Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.41Source | -1.32Source | -0.21Source | -1.05Source | -0.37Source | -1.31Source | -3.03Source | -5.29Source | -3.93Source | -5.05Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 73,396,435Source | 64,627,847Source | 83,747,104Source | 72,466,203Source | 82,050,618Source | 71,969,411Source | 72,918,764Source | 63,176,210Source | 51,289,092Source | 39,118,215Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 73,396,435Source | 64,627,847Source | 83,747,104Source | 72,466,203Source | 82,050,618Source | 71,969,411Source | 72,918,764Source | 63,176,210Source | 51,289,092Source | 39,118,215Source |
| Interest Expense (non-operating)USD | — | — | 16,108,000Source | 18,484,000Source | 15,103,000Source | 17,518,000Source | 15,797,000Source | 18,071,000Source | 68,115,000Source | 72,009,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | 200,000Source | — | — | — | — | 600,000Source | 800,000Source | 600,000Source | — |
| General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 100,999,000Source |
| Gross ProfitUSD | — | — | 43,314,000Source | 13,996,000Source | 59,178,000Source | 34,465,000Source | 46,305,000Source | 24,795,000Source | 152,511,000Source | 47,279,000Source | 515,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -221,247,000Source | — | — | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 41,968,000Source | 27,305,000Source |
| Investment Income, InterestUSD | — | — | 1,413,000Source | 3,711,000Source | 1,510,000Source | 1,787,000Source | 1,736,000Source | 2,640,000Source | 7,044,000Source | 15,158,000Source | 7,876,000Source | 2,132,000Source |
| Marketing and Advertising ExpenseUSD | — | — | — | 17,500,000Source | — | — | — | — | 61,300,000Source | 61,300,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | -14,702,000Source | -14,781,000Source | -13,617,000Source | -15,886,000Source | -14,892,000Source | -15,453,000Source | -61,261,000Source | -56,859,000Source | -34,280,000Source | -25,283,000Source |
| Operating ExpensesUSD | — | — | 58,585,000Source | 84,792,000Source | 63,143,000Source | 94,389,000Source | 61,782,000Source | 103,658,000Source | 312,497,000Source | 324,746,000Source | 167,827,000Source | 172,440,000Source |
| Operating Lease, ExpenseUSD | — | — | 200,000Source | 300,000Source | 200,000Source | 300,000Source | 200,000Source | 300,000Source | 1,000,000Source | 1,100,000Source | 1,100,000Source | 1,000,000Source |
| Research and Development ExpenseUSD | — | — | 7,027,000Source | 8,693,000Source | 7,813,000Source | 9,076,000Source | 7,771,000Source | 9,184,000Source | 32,780,000Source | 34,082,000Source | 49,899,000Source | 71,441,000Source |
| Restructuring and Related Cost, Incurred CostUSD | — | — | — | — | — | — | 0Source | — | 9,214,000Source | — | — | — |
Offerings
Registration 333-292596
Filing attachments
d180192dex991.htm · 8-K · 2026-10-29
Exhibit 99.1 Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update Over 2 million total VOQUEZNA® prescriptions filled through October 16, 2026 ─────────────────────────────────────────────────────────── Q3 2026 net revenues of $84.7 million increased 71% vs. Q3 2025 and 14% vs. Q2 2026 Generated positive operating cash flow for the second consecutive quarter ───────────────────────────────────────────────────────────────────────────── …
Read attachment ↗d114879dex991.htm · 8-K · 2026-07-30
EX-99.1 2 d114879dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update ~1.7 million total VOQUEZNA® prescriptions filled to date Record Q2 2026 net revenues of $74.3 million, increased 88% vs. Q2 2025 and 27% vs. Q1 2026 Q2 operating expenses of $63.1 million, reduced by 33% vs. Q2 2025 Initiating Phase 3 clinical trial evaluating as-needed dosing of VOQUEZNA® in patients with Non-Erosive G…
Read attachment ↗d140332dex991.htm · 8-K · 2026-04-30
EX-99.1 2 d140332dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update ~1.35 million total VOQUEZNA® prescriptions filled to date $58.3 million in Q1 net revenues, a 104% increase year-over-year Q1 operating expenses of $61.8 million; non-GAAP operating expenses of $56.2 million and net cash usage of ~$15 million, reflecting continued expense discipline and significant year-over-year cost reducti…
Read attachment ↗d680858dex41.htm · 8-K · 2026-01-08
Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK PHATHOM PHARMACEUTICALS, INC. Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: [ ], 2026 Phathom Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase f…
Read attachment ↗d680858dex991.htm · 8-K · 2026-01-08
Exhibit 99.1 FLORHAM PARK, N.J., January 7, 2026 - Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering. …
Read attachment ↗d680858dex992.htm · 8-K · 2026-01-08
Exhibit 99.2 Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants FLORHAM PARK, N.J., January 7, 2026 - Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today the pricing of an underwritten public offering of 6,875,000 shares of its common stock and pre-funded warrants to purchase 1,250,078 shares of commo…
Read attachment ↗